Announcing the Launch of the Life Sciences Workforce Collaborative — and a Preview of What’s Ahead

This week marks an important milestone for workforce development in the U.S. life sciences sector: the official launch of the Life Sciences Workforce Collaborative (LSWC). Formerly known as the Coalition of State Bioscience Institutes (CSBI), LSWC premiered at the 2025 BIO International Convention as a new national nonprofit—building on over a decade of state and regional leadership to expand industry-aligned solutions for talent development.

 

As the life sciences industry confronts evolving technologies, shifting economic headwinds, and persistent workforce challenges - including specialized talent needs, unmet demand for skilled biomanufacturers, positioning for future growth —LSWC offers a unified platform to scale solutions, support workforce readiness, and strengthen public-private partnerships across the country.

 

Just out of the gate, the new organization is pleased to announce a major insight-driven release later this month: the upcoming 2025 National Life Sciences Workforce Trends

 

Report, produced in partnership with TEConomy Partners and the NSF-funded InnovATEBIO National Biotech Education Center. Comprised of data from over 700 life science companies and 2.9 million job postings, the report will go live on June 24, 2025.

 

Why This Matters

The newly launched LSWC builds on more than a decade of trusted collaboration among 50+ state, regional and national life science organizations and workforce partners. Its mission: to align, advise, and accelerate talent development efforts across the entire life sciences talent pipeline—from middle school to mid-career--to build a competitive life sciences workforce.

Next week, the LSWC will launch the 2025 National Workforce Trends Report, the organization’s flagship effort. Now in its seventh edition, this biennial report draws on:

  • Responses from over 500 companies across 30 states and Puerto Rico
  • Interviews with over 200 life science executives
  • Analysis of 2.9 million unique job postings across the U.S. from the last four years

The report is the definitive source for understanding the real-world trends shaping hiring, upskilling, and STEM education engagement across the life sciences ecosystem. More to come next week.

 

What Comes Next

In the weeks ahead, we’ll be working with our partners to roll out media toolkits, schedule events, and activate coordinated campaigns to bring visibility to both the LSWC launch and the report.

 

We are deeply grateful to our investor-level supporters—AZBio/AZ Advances, BioNJ, BioUtah, California Life Sciences, Georgia Life Sciences/Institute, Colorado Bioscience Association/Institute, MichBio, NewYorkBIO/Institute, Ohio Life Sciences, Oregon Bioscience Association, SCbio, and Southern California Biomedical Council (SoCalBio)—LSWC partners and connectors, and to every organization that has shaped this initiative from the ground up.


Together, we are building a stronger, competitive, and future-ready workforce—one that ensures the U.S. remains the global leader in biotechnology, biomanufacturing, and life sciences innovation.

 

Stay tuned and learn how you can partner with us to advance the life sciences workforce.


Learn more at: www.LifeSciencesWorkforce.org
For media inquiries: connect@lifesciencesworkforce.org

BIO Statement on Most Favored Nation Policies

October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###

September GBG Report Now Available – Federal Funding Insights for Georgia Life Sciences Members

September 11, 2025
Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.

Advocating for U.S. Agricultural Biotechnology Leadership

By Maria Thacker Goethe • September 5, 2025
Protecting U.S. Leadership in Agricultural Biotechnology
MORE POSTS